Christoffer R. Gebhardt
Expertise in
3
conditions

Christoffer R. Gebhardt

Hamburg, HH, DE 
Expertise in
3
conditions
Hamburg, HH, DE 

Overview

Christoffer Gebhardt practices practicing medicine in Hamburg, Germany.

Mr. Gebhardt is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Melanoma, Metastatic Uveal Melanoma, Uveal Melanoma, and Basal Cell Skin Cancer.

He is actively involved in clinical research, co-authoring 143 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Hamburg, HH, Germany
Other Locations
Eppendorf, HH, Germany
Heidelberg, BW, Germany
Mannheim, BW, Germany
Bremen, HB 28359, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Enrollment Status: Completed
Publish Date: March 17, 2026
Intervention Type: Biological, Drug
Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Enrollment Status: Completed
Publish Date: April 09, 2025
Intervention Type: Drug
Study Drugs: Vemurafenib, Cobimetinib, Atezolizumab
Study Phase: Phase 2
A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: January 27, 2025
Intervention Type: Biological, Drug
Study Drugs: Cemiplimab, RP1
Study Phase: Phase 2
Adjuvant Nivolumab Treatment in Stage II High-risk Melanoma - A Randomized, Controlled, Phase III Trial With Biomarker-based Risk Stratification
Adjuvant Nivolumab Treatment in Stage II High-risk Melanoma - A Randomized, Controlled, Phase III Trial With Biomarker-based Risk Stratification
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2024
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 3
View 3 Less Clinical Trials

143 Total Publications

Beyond the First Graft: Skin Cancer Risk and Risk Stratification in Retransplanted Solid Organ Recipients.
Beyond the First Graft: Skin Cancer Risk and Risk Stratification in Retransplanted Solid Organ Recipients.
Journal: The British journal of dermatology
Published: May 05, 2026

Frequently Asked Questions about Christoffer R. Gebhardt

Is Christoffer R. Gebhardt a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Christoffer R. Gebhardt is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Christoffer R. Gebhardt participate in research or clinical trials?

Yes. Christoffer R. Gebhardt has published 143 articles and abstracts on conditions like Melanoma. You can view a list of Christoffer R. Gebhardt's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Gebhardt's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile